The metabolism of Captopril can be decreased when combined with Ropinirole. The risk or severity of adverse effects can be increased when Amphotericin B is combined with Ropinirole. The metabolism of Etoposide can be decreased when combined with Ropinirole. The metabolism of Apixaban can be decreased when combined with Ropinirole. The metabolism of Icotinib can be decreased when combined with Ropinirole. The metabolism of Fluorouracil can be decreased when combined with Ropinirole. Eltanolone may increase the sedative activities of Ropinirole. The serum concentration of Ropinirole can be increased when it is combined with Conjugated estrogens. Lithium may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Diclofenamide. The serum concentration of Ropinirole can be increased when it is combined with Propafenone. The serum concentration of Ropinirole can be increased when it is combined with Palbociclib. The metabolism of Daunorubicin can be decreased when combined with Ropinirole. Pizotifen may increase the sedative activities of Ropinirole. Brimonidine may increase the sedative activities of Ropinirole. The metabolism of Escitalopram can be decreased when combined with Ropinirole. Melatonin may increase the sedative activities of Ropinirole. Esmirtazapine may decrease the antihypertensive activities of Ropinirole. The metabolism of Methyprylon can be decreased when combined with Ropinirole. The serum concentration of Ropinirole can be increased when it is combined with Estrogens, esterified. The metabolism of Temafloxacin can be decreased when combined with Ropinirole. The metabolism of Ropinirole can be decreased when combined with Lopinavir. The risk or severity of adverse effects can be increased when Ropinirole is combined with Amyl Nitrite. The therapeutic efficacy of Ropinirole can be decreased when used in combination with Mianserin. The metabolism of Acenocoumarol can be decreased when combined with Ropinirole. The metabolism of Ropinirole can be decreased when combined with Nefazodone. Topiramate may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Ramipril. The metabolism of Ropinirole can be decreased when combined with Sulfisoxazole. Pentazocine may increase the sedative activities of Ropinirole. Pomalidomide may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Minoxidil. The metabolism of Ibrutinib can be decreased when combined with Ropinirole. The metabolism of Chloroquine can be decreased when combined with Ropinirole. Amisulpride may increase the sedative activities of Ropinirole. The metabolism of Triamterene can be decreased when combined with Ropinirole. Cetirizine may increase the sedative activities of Ropinirole. Tandospirone may increase the sedative activities of Ropinirole. The metabolism of Nicotine can be decreased when combined with Ropinirole. The metabolism of Frovatriptan can be decreased when combined with Ropinirole. The metabolism of Enasidenib can be decreased when combined with Ropinirole. The metabolism of Pantoprazole can be decreased when combined with Ropinirole. The metabolism of Tolterodine can be decreased when combined with Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Felodipine. Methocarbamol may increase the sedative activities of Ropinirole. The metabolism of Ropinirole can be decreased when combined with Cobicistat. The metabolism of Valbenazine can be decreased when combined with Ropinirole. The metabolism of Dinoprostone can be decreased when combined with Ropinirole. Brexpiprazole may increase the sedative activities of Ropinirole. The metabolism of Ropinirole can be decreased when combined with Fluconazole. Cyclobenzaprine may increase the sedative activities of Ropinirole. The metabolism of Ropinirole can be decreased when combined with Pargyline. The therapeutic efficacy of Propericiazine can be decreased when used in combination with Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Sodium Nitrite. Perospirone may increase the sedative activities of Ropinirole. Baclofen may increase the sedative activities of Ropinirole. The metabolism of Lumiracoxib can be decreased when combined with Ropinirole. Eszopiclone may increase the sedative activities of Ropinirole. The metabolism of Clenbuterol can be decreased when combined with Ropinirole. The metabolism of Levomilnacipran can be decreased when combined with Ropinirole. The metabolism of Mirabegron can be decreased when combined with Ropinirole. Ropinirole may increase the atrioventricular blocking (AV block) activities of Talinolol. The risk or severity of adverse effects can be increased when Rasagiline is combined with Ropinirole. Pramocaine may increase the sedative activities of Ropinirole. The metabolism of Nabumetone can be decreased when combined with Ropinirole. Phenytoin may increase the sedative activities of Ropinirole. Ropinirole may increase the atrioventricular blocking (AV block) activities of Labetalol. Milnacipran may decrease the antihypertensive activities of Ropinirole. The metabolism of Ranitidine can be decreased when combined with Ropinirole. Ropinirole may increase the atrioventricular blocking (AV block) activities of Landiolol. The metabolism of Ropinirole can be decreased when combined with Mexiletine. The metabolism of Ajmaline can be decreased when combined with Ropinirole. The metabolism of Ropinirole can be decreased when combined with Lovastatin. The metabolism of Rotigotine can be decreased when combined with Ropinirole. Ropinirole may increase the atrioventricular blocking (AV block) activities of Bufuralol. The metabolism of Epinastine can be decreased when combined with Ropinirole. Proparacaine may increase the sedative activities of Ropinirole. Amperozide may increase the sedative activities of Ropinirole. The metabolism of Guanabenz can be decreased when combined with Ropinirole. Ropinirole may increase the atrioventricular blocking (AV block) activities of Esmolol. The metabolism of Ropinirole can be decreased when combined with Pirlindole. Secobarbital may increase the sedative activities of Ropinirole. Ramelteon may increase the sedative activities of Ropinirole. The metabolism of Riluzole can be decreased when combined with Ropinirole. The serum concentration of Ropinirole can be increased when it is combined with Vemurafenib. Norflurane may increase the sedative activities of Ropinirole. The metabolism of Oxaliplatin can be decreased when combined with Ropinirole. Desipramine may increase the sedative activities of Ropinirole. Clidinium may increase the sedative activities of Ropinirole. Zuclopenthixol may increase the sedative activities of Ropinirole. Ondansetron may increase the sedative activities of Ropinirole. Propoxycaine may increase the sedative activities of Ropinirole. Pipamperone may increase the sedative activities of Ropinirole. Doxepin may increase the sedative activities of Ropinirole. Azelastine may increase the sedative activities of Ropinirole. Dihydroetorphine may increase the sedative activities of Ropinirole. The metabolism of Ropinirole can be decreased when combined with Procarbazine. Pentobarbital may increase the sedative activities of Ropinirole. The metabolism of Acetaminophen can be decreased when combined with Ropinirole. The metabolism of Ropinirole can be decreased when combined with Boceprevir. The risk or severity of adverse effects can be increased when Ropinirole is combined with Nitroprusside. The risk or severity of adverse effects can be increased when Ropinirole is combined with Hydralazine. The metabolism of Dasabuvir can be decreased when combined with Ropinirole. The metabolism of Carmustine can be decreased when combined with Ropinirole. Bromazepam may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Benazepril. The risk or severity of adverse effects can be increased when Ropinirole is combined with Furosemide. The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ropinirole resulting in a loss in efficacy. Dezocine may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Losartan. Ethyl chloride may increase the sedative activities of Ropinirole. Enflurane may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Fosinopril. The serum concentration of Ropinirole can be increased when it is combined with Aprepitant. The serum concentration of Ropinirole can be increased when it is combined with Abiraterone. Phenoxyethanol may increase the sedative activities of Ropinirole. The metabolism of Almotriptan can be decreased when combined with Ropinirole. Pipotiazine may increase the sedative activities of Ropinirole. Dantrolene may increase the sedative activities of Ropinirole. Clobazam may increase the sedative activities of Ropinirole. The metabolism of Warfarin can be decreased when combined with Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Irbesartan. Zopiclone may increase the sedative activities of Ropinirole. Flupentixol may increase the sedative activities of Ropinirole. Ropinirole may increase the atrioventricular blocking (AV block) activities of Penbutolol. Ropinirole may increase the atrioventricular blocking (AV block) activities of Alprenolol. Paliperidone may increase the sedative activities of Ropinirole. The metabolism of Palonosetron can be decreased when combined with Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Mecamylamine. The metabolism of Trabectedin can be decreased when combined with Ropinirole.